Sarah E. Glass

ASCI member Coffey et al. @VUMChealth establish DPEP1’s importance in maintaining microsatellite stable colorectal cancer, and its ability to shape the tumor microenvironment: insight.jci.org/articles/view/…

🧬 A 2025 JCI Insight study from Vanderbilt used LSALT peptide to reduce neutrophil binding to colorectal cancer (CRC) cells, highlighting DPEP1’s immune role. The authors suggest LSALT could pair with ICI (immune checkpoint inhibitors) and could lead to a viable therapeutic. Arch holds patents for its DPEP1 inhibition drug candidates, including LSALT peptide, covering use in cancer applications. 🔗 insight.jci.org/articles/view/… #LSALTpeptide #DPEP1 #ArchScience $ARCH.V $ACHFF

🔬 New research in @JCI_insight by @SciComSarah, @VanderbiltCDB shows that removing a single protein, DPEP1, can dramatically change how #coloncancer develops—leading to more aggressive tumors that resemble a type more responsive to immunotherapy. 👉 doi.org/10.1172/jci.in…

👋Interested in the connections between #GPI-anchored proteins and their #extracellular carriers in #colorectal cancer? 👀See the new review from @SciComSarah @RobertJCoffey @VUMCDiscoveries just out in @EVCNA. 🔗evcna.com/article/view/5… #biomarkers #exosomes

Ready to learn at ASI2022 for my first time in Australia @ASImmunology

Learned so much about career opportunities post-PhD in the science writing space with @CzerneReid #SciWriMentoring